|
JPH075457B2
(ja)
*
|
1983-08-16 |
1995-01-25 |
ザ ウエルカム フアウンデ−シヨン リミテツド |
調節された方法による有効成分の放出を可能にする医薬組成物
|
|
US4600773A
(en)
*
|
1983-12-01 |
1986-07-15 |
Eli Lilly And Company |
Crystalline cephalexin hydrochloride monohydrate
|
|
US4624847A
(en)
*
|
1985-04-22 |
1986-11-25 |
Alza Corporation |
Drug delivery device for programmed delivery of beneficial drug
|
|
US4704118A
(en)
*
|
1985-08-16 |
1987-11-03 |
Alza Corporation |
Ruminant dispensing device with thermo-activated memory
|
|
ES8800043A1
(es)
*
|
1985-08-16 |
1987-10-16 |
Alza Corp |
Un dispositivo distribuidor para descargar una formulacion de agente beneficioso a un entorno de uso
|
|
US4963141A
(en)
*
|
1985-08-16 |
1990-10-16 |
Alza Corporation |
Dispensing system for administering beneficial agent formulation to ruminants
|
|
US4723957A
(en)
*
|
1986-02-07 |
1988-02-09 |
Alza Corp. |
System for delivering drug with enhanced bioacceptability
|
|
US4716496A
(en)
*
|
1986-05-09 |
1987-12-29 |
Eaton Corporation |
Panel-mounted control station housing
|
|
US4814181A
(en)
*
|
1987-09-03 |
1989-03-21 |
Alza Corporation |
Dosage form comprising fast agent delivery followed by slow agent delivery
|
|
US4816263A
(en)
*
|
1987-10-02 |
1989-03-28 |
Alza Corporation |
Dosage form for treating cardiovascular diseases comprising isradipine
|
|
ES2037179T3
(es)
*
|
1987-11-25 |
1993-06-16 |
American Cyanamid Company |
Sistema de liberacion sostenida (controlada) para bloqueadores de canales de calcio de dihidropiridina.
|
|
US4837111A
(en)
*
|
1988-03-21 |
1989-06-06 |
Alza Corporation |
Dosage form for dispensing drug for human therapy
|
|
US4855141A
(en)
*
|
1988-03-25 |
1989-08-08 |
Alza Corporation |
Device comprising means for protecting and dispensing fluid sensitive medicament
|
|
US4859470A
(en)
*
|
1988-06-02 |
1989-08-22 |
Alza Corporation |
Dosage form for delivering diltiazem
|
|
IL91398A
(en)
*
|
1988-08-30 |
1994-05-30 |
Pfizer |
Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
|
|
US5612059A
(en)
*
|
1988-08-30 |
1997-03-18 |
Pfizer Inc. |
Use of asymmetric membranes in delivery devices
|
|
GR1000270B
(el)
*
|
1988-09-30 |
1992-05-12 |
Alza Corp |
Μορφη δοσολογιας για θεραπεια καρδιαγγειακων ασθενειων.
|
|
IL92966A
(en)
*
|
1989-01-12 |
1995-07-31 |
Pfizer |
Dispensing devices powered by hydrogel
|
|
US5030452A
(en)
*
|
1989-01-12 |
1991-07-09 |
Pfizer Inc. |
Dispensing devices powered by lyotropic liquid crystals
|
|
US5108756A
(en)
*
|
1989-01-12 |
1992-04-28 |
Pfizer Inc. |
Dispensing devices powered by lyotropic liquid crystals
|
|
EP0408496A3
(en)
*
|
1989-07-12 |
1992-07-01 |
Ciba-Geigy Ag |
Solid dosage form for pharmaceutical substances
|
|
US5000962A
(en)
*
|
1989-08-25 |
1991-03-19 |
Schering Corporation |
Long acting diltiazem formulation
|
|
US4992277A
(en)
*
|
1989-08-25 |
1991-02-12 |
Schering Corporation |
Immediate release diltiazem formulation
|
|
US5067960A
(en)
*
|
1989-12-06 |
1991-11-26 |
Medtronic, Inc. |
Muscle fitness detection by colorimetry
|
|
US5190763A
(en)
*
|
1990-05-07 |
1993-03-02 |
Alza Corporation |
Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
|
|
US5081161A
(en)
*
|
1990-06-15 |
1992-01-14 |
E. I. Du Pont De Nemours And Company |
Process for making shaped articles of a thermoplastic resin having a microcellular structure
|
|
NZ238867A
(en)
*
|
1990-07-12 |
1993-08-26 |
Alza Corp |
Dosage form for delayed release comprising pharmaceutically active substance and a drug-release hindering means and a second composition which imbibes fluid, expands, and ejects the active substance from the device
|
|
DK0542926T3
(da)
*
|
1990-08-07 |
1995-05-15 |
Pfizer |
Brug af grænsefladepolymeriserede membraner i frigivelsesanordninger
|
|
US5166145A
(en)
*
|
1990-09-10 |
1992-11-24 |
Alza Corporation |
Antiemetic therapy
|
|
ES2053339T3
(es)
*
|
1990-09-28 |
1994-07-16 |
Pfizer |
Dispositivo dispensador conteniendo un medio hidrofobo.
|
|
US5208037A
(en)
*
|
1991-04-22 |
1993-05-04 |
Alza Corporation |
Dosage forms comprising polymers comprising different molecular weights
|
|
EP0612519B1
(en)
*
|
1993-02-23 |
2001-04-04 |
Wolfgang Dr. Werner |
Use of a calcium formulation in a medicament for therapeutic application to milk cows suffering from hypocalcaemia
|
|
US6440457B1
(en)
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
|
US6287598B1
(en)
*
|
1993-05-28 |
2001-09-11 |
Alza Corporation |
Method for providing sustained antiepileptic therapy
|
|
HU213407B
(en)
*
|
1993-12-09 |
1997-06-30 |
Egyt Gyogyszervegyeszeti Gyar |
Process for producing tablet with diffusive-osmotic release
|
|
US5460826A
(en)
*
|
1994-06-27 |
1995-10-24 |
Alza Corporation |
Morphine therapy
|
|
US5948787A
(en)
|
1997-02-28 |
1999-09-07 |
Alza Corporation |
Compositions containing opiate analgesics
|
|
DE19962924A1
(de)
|
1999-12-24 |
2001-07-05 |
Bayer Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
|
BR0115382A
(pt)
*
|
2000-10-30 |
2003-09-16 |
Euro Celtique Sa |
Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica
|
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
|
DE10129725A1
(de)
|
2001-06-20 |
2003-01-02 |
Bayer Ag |
Kombinationstherapie substituierter Oxazolidinone
|
|
DE10300111A1
(de)
|
2003-01-07 |
2004-07-15 |
Bayer Healthcare Ag |
Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
|
|
JP5666075B2
(ja)
*
|
2003-09-19 |
2015-02-12 |
サン・ファーマシューティカル・インダストリーズ・リミテッドSun Pharmaceutical Industries Limited |
経口薬送達システム
|
|
US10213387B2
(en)
|
2003-09-19 |
2019-02-26 |
Sun Pharma Advanced Research Company Ltd. |
Oral drug delivery system
|
|
US10226428B2
(en)
|
2003-09-19 |
2019-03-12 |
Sun Pharma Advanced Research Company Ltd. |
Oral drug delivery system
|
|
DE10355461A1
(de)
|
2003-11-27 |
2005-06-23 |
Bayer Healthcare Ag |
Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
|
|
DE102004062475A1
(de)
*
|
2004-12-24 |
2006-07-06 |
Bayer Healthcare Ag |
Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
|
|
EP1685841A1
(en)
|
2005-01-31 |
2006-08-02 |
Bayer Health Care Aktiengesellschaft |
Prevention and treatment of thromboembolic disorders
|
|
DE102005031577A1
(de)
|
2005-07-06 |
2007-01-11 |
Bayer Healthcare Ag |
Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
|
|
DE102005045518A1
(de)
|
2005-09-23 |
2007-03-29 |
Bayer Healthcare Ag |
2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
|
|
DE102005047561A1
(de)
|
2005-10-04 |
2007-04-05 |
Bayer Healthcare Ag |
Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
|
|
PT1934208E
(pt)
|
2005-10-04 |
2011-06-01 |
Bayer Schering Pharma Ag |
Nova forma polimorfa de 5-cloro-n-({(5s)-2-oxo-3-[4-(3- oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2- tiofenocarboxamida
|
|
DE102008059206A1
(de)
|
2008-11-27 |
2010-06-10 |
Bayer Schering Pharma Aktiengesellschaft |
Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
|
|
BRPI0925100A2
(pt)
*
|
2009-06-02 |
2016-07-19 |
Dow Global Technologies Llc |
forma de dosagem osmótica e processo para preparar uma forma de dosagem osmótica
|
|
DE102011007272A1
(de)
|
2011-04-13 |
2012-10-18 |
Bayer Pharma Aktiengesellschaft |
Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
|
|
MX2014013320A
(es)
|
2012-05-07 |
2015-08-10 |
Bayer Pharma AG |
Procedimiento de fabricacion de una forma de dosificacion farmaceutica que comprende nifedipina y candesartan cilexetilo.
|
|
UY34856A
(es)
|
2012-07-03 |
2013-12-31 |
Bayer Pharma AG |
Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
|
|
JP5941117B2
(ja)
*
|
2014-10-17 |
2016-06-29 |
ダウ グローバル テクノロジーズ エルエルシー |
徐放製剤
|
|
US10905667B2
(en)
|
2018-07-24 |
2021-02-02 |
Bayer Pharma Aktiengesellschaft |
Orally administrable modified-release pharmaceutical dosage form
|
|
JP2021531297A
(ja)
|
2018-07-24 |
2021-11-18 |
バイエル・アクチエンゲゼルシヤフト |
経口投与可能であり、修飾された放出を有する薬学的投薬形態
|
|
AU2019311234A1
(en)
|
2018-07-24 |
2021-02-04 |
Bayer Aktiengesellschaft |
Pharmaceutical dosage form which can be administered orally and has modified release
|